Introduction {#S0001}
============

Based on the recent data, colorectal cancer (CRC) is the third most common cancer and causes a huge number of deaths.[@CIT0001] Although great advance has been obtained on strategies for CRC therapy, the mortality of CRC remains very high.[@CIT0002] The 5-year survival rate of CRC patients is very low.[@CIT0003] Thus, the molecular mechanism of CRC development requires to be understood and novel therapeutic targets are urgently waiting for determination.

Circular RNAs (circRNAs) are a novel kind of noncoding RNAs and characterized by a covalently closed loop and lacking 5ʹ caps and 3ʹ poly(A) tails.[@CIT0004] In the past years, increasing numbers of evidence have revealed the vital importance of circRNAs in human diseases, including cancers.[@CIT0005],[@CIT0006] Many biological processes, such as cell proliferation, metastasis, differentiation and death, could be regulated by circRNAs in cancer.[@CIT0007] For instance, circRNA cTFRC interacts with miR-107 to enhance the growth and metastasis of bladder cancer.[@CIT0008] CircPSMC3 competitively sponges miR-29605p to inhibit cell proliferation, migration and invasion in gastric cancer.[@CIT0009] CircRNA hsa_circ_0072309 represses growth and invasiveness of breast cancer through sponging miR-492.[@CIT0010] These researchers indicate the key regulatory roles of circRNAs in tumorigenesis. However, the mechanism of circRNA regulating CRC still remains poorly understood.

Hsa_circRNA_102958 is a novel circRNA and its function has not been well investigated. A recent report indicated that hsa_circRNA_102958 may be a diagnostic biomarker for gastric cancer.[@CIT0011] However, the function of hsa_circRNA_102958 in CRC is unclear. In this study, we found that hsa_circRNA_102958 expression was upregulated in CRC tissues and cell lines. Hsa_circRNA_102958 high expression in CRC patients indicated a poor prognosis. Silencing of hsa_circRNA_102958 significantly suppresses the proliferation, migration and invasion of CRC cells in vitro. Moreover, tumor growth of CRC was also inhibited by hsa_circRNA_102958 knockdown in vivo. Hsa_circRNA_102958 was demonstrated to interact with miR-585 and promote CDC25B expression mechanistically. In conclusion, we identified that hsa_circRNA_102958/miR-585/CDC25B axis is a novel and pivot signaling pathway involved in CRC progression.

Materials and methods {#S0002}
=====================

Patients and samples {#S0002-S2001}
--------------------

All 58 patient samples were obtained from our hospital. Tissues were stored in liquid nitrogen after collection. No patients were treated by chemotherapy or radiotherapy. This study was approved by the Ethics Committee of Wenzhou Central Hospital. Informed consent was signed by all patients. Experiments involving human tissues were conducted in accordance with the Declaration of Helsinki.

Cell culture {#S0002-S2002}
------------

CRC cell lines, including LoVo, SW480, SW620, HT29, HCT8 and HCT116 cells, and normal colon epithelial cell line FHC were obtained from Cell Bank of Type Culture Collection (Shanghai City, China). Cells were cultured using DMEM (Invitrogen) containing 10% FBS (Gibco,Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco).

Quantitative real-time PCR {#S0002-S2003}
--------------------------

Total RNAs were extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Quantitative real-time PCR analysis was conducted as previously reported.[@CIT0005]

Bioinformatics analysis {#S0002-S2004}
-----------------------

The potential target of hsa_circRNA_102958 was analyzed by using circinteractome (<https://circinteractome.nia.nih.gov/>). Potential targets of miR-585 were predicted by using TargetScan (<http://www.targetscan.org/vert_71/>).

Luciferase reporter assay {#S0002-S2005}
-------------------------

The wild type (WT) or mutant sequence of hsa_circRNA_102958 or CDC25B was cloned into psiCHECK-2 vector (Promega, Madison, WI, USA). Then, reporters and miR-585 mimics or controls were transfected into CRC cells using Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA, USA); 48 hrs later, the relative luciferase activity was measured by using the Dual-Luciferase Reporter Assay System (Promega). Renilla luciferase activity is internal control.

CCK8 assay {#S0002-S2006}
----------

CRC cells were seeded into the 96-well plates at a density of 2000 cells per well. Then, cells were cultured for 24, 48 and 72 hrs. Later, the Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) was added and incubated for 4 hrs. Then, absorbance at 450 nm was then detected by using a Varioskan Flash Spectral Scanning Multimode Reader (Thermo Fisher Scientific, Waltham, MA, USA).

Transwell assay {#S0002-S2007}
---------------

Cell migration and invasion were evaluated by using Transwell chamber (Corning Inc., Corning, NY, USA) and Matrigel (Corning Inc.) as previously described.[@CIT0002]

In vivo assay {#S0002-S2008}
-------------

Four-week-old male BALB/c nude mice were divided into 2 groups (n=5 for each group). Then, HCT116 cells (hsa_circRNA_102958 silencing or control) were subcutaneously inoculated into the right flank of each nude mouse. Every 1 week, the tumor volumes were measured by the formula: Volume = 1/2 (length × width^2^). This assay was approved by the Ethics Committee of Wenzhou Central Hospital. All animal operations were performed in accordance with the Animal Policy and Welfare Committee of Wenzhou Central Hospital.

Statistical analysis {#S0002-S2009}
--------------------

GraphPad Prism 6.0 was used for Statistical analysis (GraphPad Software, Inc., La Jolla, CA, USA). Student's *t*-test or one-way ANOVA was used for calculating significant differences. Survival rate was measured by Kaplan--Meier method and log-rank test. The correlations were determined through Pearson's correlation coefficients. All experiments were conducted at least three times. *P*\< 0.05 was considered significantly different.

Results {#S0003}
=======

Expression level of hsa_circRNA_102958 was upregulated in CRC {#S0003-S2001}
-------------------------------------------------------------

The expression of hsa_circRNA_102958 in CRC tissues was analyzed by quantitative real-time PCR. We found that hsa_circRNA_102958 level was increased in tumor tissues (n=58) compared to adjacent normal tissues (n=58) ([Figure 1A](#F0001){ref-type="fig"}). To further validate it, in situ hybridization was conducted and similar results were achieved ([Figure 1B](#F0001){ref-type="fig"}). Furthermore, we found that hsa_circRNA_102958 expression was positively correlated with clinical stage ([Figure 1C](#F0001){ref-type="fig"}) and lymph node metastasis ([Figure 1D](#F0001){ref-type="fig"}). Consistently, hsa_circRNA_102958 expression was also upregulated in CRC cell lines compared to FHC cells ([Figure 1E](#F0001){ref-type="fig"}). Then, the samples were divided into hsa_circRNA_102958 high expression and low expression groups based on the median value. Survival rate was calculated by Kaplan--Meier curve. Result showed that hsa_circRNA_102958 high expression group displayed a low survival rate ([Figure 1F](#F0001){ref-type="fig"}).Figure 1Expression level of hsa_circRNA_102958 was upregulated in CRC. (**A**) Relative expression of hsa_circRNA_102958 in 58 paired colorectal cancer (CRC) tissues and normal controls by quantitative real-time PCR. (**B**) In situ hybridization (ISH) was used to analyze hsa_circRNA_102958 expression in paired CRC tissues and normal controls. Scale bar, 50 μm. (**C**) Expression of hsa_circRNA_102958 in Stages I/II and Stages III/IV was determined. (**D**) Expression of hsa_circRNA_102958 in CRC tissues with lymph node metastasis (N1/N2) or not (N0) was analyzed. (**E**) Differential expression patterns of hsa_circRNA_102958 in CRC cell lines and FHC cells by quantitative real-time PCR. (**F**) High hsa_circRNA_102958 expression indicated low survival rate in CRC patients. \**P*\<0.05, \*\**P*\<0.01 and \*\*\**P*\<0.001.

Loss of hsa_circRNA_102958 suppressed proliferation, migration and invasion of CRC cells {#S0003-S2002}
----------------------------------------------------------------------------------------

To investigate the potential roles of hsa_circRNA_102958, SW480 and HCT116 cells were selected for experiments because hsa_circRNA_102958 expression was the highest in these two cells among all detected cell lines ([Figure 1E](#F0001){ref-type="fig"}). Hsa_circRNA_102958 expression was decreased by using specific siRNAs ([Figure 2A](#F0002){ref-type="fig"}). Through CCK8 assay, we found that hsa_circRNA_102958 knockdown significantly suppressed the proliferation of SW480 and HCT116 cells ([Figure 2B](#F0002){ref-type="fig"}). Colony formation further validated it ([Figure 2C](#F0002){ref-type="fig"}). Transwell assay showed that hsa_circRNA_102958 knockdown inhibited the migration and invasion of SW480 and HCT116 cells ([Figure 2D](#F0002){ref-type="fig"} and [E](#F0002){ref-type="fig"}). To further confirm the effect of hsa_circRNA_102958 on CRC growth in vivo, we performed xenograft assay. We found that hsa_circRNA_102958 silencing significantly inhibited tumor volumes ([Figure 2F](#F0002){ref-type="fig"}). Thus, hsa_circRNA_102958 promotes proliferation, migration and invasion of CRC.Figure 2Loss of hsa_circRNA_102958 suppressed proliferation, migration and invasion of colorectal cancer (CRC) cells. (**A**) Hsa_circRNA_102958 expression was decreased in SW480 and HCT116 cells after transfection with si-circRNA. (**B** and **C**) The proliferation was inhibited after hsa_circRNA_102958 silencing as shown by CCK8 and colony formation assays. (**D** and **E**) Transwell assay indicated that hsa_circRNA_102958 knockdown suppressed the migration and invasion of SW480 and HCT116 cells. (**F**) Xenograft experiment indicated that tumor volumes were reduced after hsa_circRNA_102958 silencing. \**P*\<0.05 and \*\**P*\<0.01.

Hsa_circRNA_102958 was a sponge for miR-585 and miR-585 targeted CDC25B {#S0003-S2003}
-----------------------------------------------------------------------

Previous studies have shown that circRNA are good sponges for miRNAs.[@CIT0007],[@CIT0010] Thus, we analyzed the potential targets of hsa_circRNA_102958. Through bioinformatics analysis, we found that hsa_circRNA_102958 might be the sponge for miR-585 (miR-585-3p) because miR-585 ranked top among all candidates by bioinformatics analysis ([Figure 3A](#F0003){ref-type="fig"}). To validate it, we performed luciferase reporter assay. We found that the activity of WT hsa_circRNA_102958 reporter was suppressed by miR-585 mimics in SW480 and HCT116 cells ([Figure 3B](#F0003){ref-type="fig"}). Besides, RNA pulldown also indicated that biotin-labeled WT miR-585 could interact with hsa_circRNA_102958 ([Figure 3C](#F0003){ref-type="fig"}), suggesting their direct interaction. Notably, we observed that hsa_circRNA_102958 silencing led to increased expression of miR-585 in CRC cells ([Figure 3D](#F0003){ref-type="fig"}). Furthermore, we found that miR-585 expression was downregulated and negatively correlated with hsa_circRNA_102958 levels in CRC tissues ([Figure 3E](#F0003){ref-type="fig"} and [F](#F0003){ref-type="fig"}). Afterwards, we analyzed the potential targets of miR-585. According to bioinformatics analysis, we identified CDC25B because it ranked top and has been reported to participate in tumorigenesis ([Figure 3G](#F0003){ref-type="fig"}). Through luciferase reporter assay, we found that the activity of WT CDC25B-3ʹ UTR was significantly reduced by miR-585 mimics ([Figure 3H](#F0003){ref-type="fig"}). Moreover, miR-585 mimics inhibited the expression of CDC25B in CRC cells ([Figure 3I](#F0003){ref-type="fig"} and [J](#F0003){ref-type="fig"}) and miR-585 inhibitors promoted CDC25B expression ([Figure 3I](#F0003){ref-type="fig"}). We then analyzed the expression patterns of CDC25B. Quantitative real-time PCR indicated that CDC25B levels were upregulated in CRC tissues ([Figure 3K](#F0003){ref-type="fig"}), which was consistent with the TCGA data ([Figure 3L](#F0003){ref-type="fig"}). Interestingly, we observed that CDC25B expression was negatively correlated with miR-585 in CRC tissues ([Figure 3M](#F0003){ref-type="fig"}). Thus, above data demonstrates that miR-585 is sponged by hsa_circRNA_102958 and targets CDC25B in CRC.Figure 3Hsa_circRNA_102958 was a sponge for miR-585 and miR-585 targeted CDC25B. (**A**) Analysis of binding sites with miR-585 in hsa_circRNA_102958. (**B**) Luciferase reporter assay indicated that hsa_circRNA_102958-WT reporter activity was inhibited by miR-585 mimics. (**C**) RNA pulldown assay indicated that biotin-labeled miR-585-WT precipitated hsa_circRNA_102958 in SW480 and HCT116 cells. (**D**) Hsa_circRNA_102958 silencing promoted miR-585 expression in SW480 and HCT116 cells. (**E**) miR-585 expression was downregulated in colorectal cancer (CRC) tissues. (**F**) miR-585 expression was negatively correlated with hsa_circRNA_102958 in CRC tissues. (**G**) Analysis of binding sites with miR-585 in CDC25B 3ʹ-UTR. (**H**) Luciferase reporter assay indicated that CDC25B 3ʹ-UTR-WT reporter activity was inhibited by miR-585 mimics. (**I** and **J**) CDC25B expression was suppressed by miR-585 mimics. (**K**) CDC25B expression was upregulated in CRC tissues by quantitative real-time PCR. (**L**) Based on TCGA data, CDC25B expression was increased in CRC tissues. (**M**) CDC25B expression was reversely correlated with miR-585 in CRC tissues. \*\**P*\<0.01 and \*\*\**P*\<0.001.

Hsa_circRNA_102958 promoted CRC progression through CDC25B {#S0003-S2004}
----------------------------------------------------------

To determine whether hsa_circRNA_102958 promotes CRC progression through CDC25B, we measured the effect of hsa_circRNA_102958 on CDC25B expression. We found that CDC25B expression was decreased by hsa_circRNA_102958 knockdown ([Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}), whereas inhibition of miR-585 reversed it ([Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}). Thus, hsa_circRNA_102958 promotes CDC25B expression by inhibiting miR-585. Then, we overexpressed CDC25B. As shown, CDC25B overexpression reversed the effects of hsa_circRNA_102958 knockdown on cell proliferation, migration and invasion ([Figure 4C](#F0004){ref-type="fig"}--[E](#F0004){ref-type="fig"}). Taken together, our results illustrate the key roles of hsa_circRNA_102958/miR-585/CDC25B axis in CRC.Figure 4Hsa_circRNA_102958 promoted CRC progression through CDC25B. (**A** and **B**) CDC25B expression was detected in SW480 and HCT116 cells transfected with siRNA or miR-585 inhibitors. (**C**--**E**) CCK8 assay showed that CDC25B overexpression reversed the effects of hsa_circRNA_102958 silencing on proliferation, migration and invasion. \*\**P*\<0.01.

Discussion {#S0004}
==========

In the current study, we investigated the oncogenic roles of hsa_circRNA_102958 in CRC progression. We showed that hsa_circRNA_102958 expression was significantly upregulated in CRC tissues compared to adjacent normal tissues. Furthermore, hsa_circRNA_102958 level was positively correlated with clinical stage. And, increased expression of hsa_circRNA_102958 predicted poor prognosis. Loss-of-function assays indicated that hsa_circRNA_102958 silencing significantly suppressed the proliferation, migration and invasion of CRC cells. We also found that hsa_circRNA_102958 was a sponge for miR-585 and upregulated miR-585 expression.

Accumulating studies have demonstrated the essential functions of circRNAs in cancers, including CRC.[@CIT0002] Several evidences reveal that circRNAs participate in regulating various life processes of CRC cells, such as differentiation, proliferation and migration. For example, hsa_circ_0136666 increases the growth and metastasis of CRC by modulating miR-136/SH2B1 pathway.[@CIT0012] CircRNA_100290 contributes to CRC development via miR-516b/FZD4/Wnt/β-catenin signaling cascade.[@CIT0013] Overexpression of hsa_circ_0000069 enhances the growth and metastasis of CRC.[@CIT0014] However, the relationship between circRNA and CRC progression still remains poorly explored. And the roles of hsa_circRNA_102958 are largely unknown. In our study, we found that hsa_circRNA_102958 expression was significantly upregulated in CRC tissues. Through CCK8 and colony formation assays, we demonstrated that hsa_circRNA_102958 promotes CRC cell proliferation. By using Transwell assay, we revealed that hsa_circRNA_102958 silencing suppressed migration and invasion of CRC cells. Xenograft assay also demonstrated the oncogenic roles of hsa_circRNA_102958. Taken together, our work demonstrated that hsa_circRNA_102958 promoted CRC cell proliferation, migration and invasion in vitro and in vivo.

To further investigate the molecular mechanism, we used bioinformatics method to search the potential miRNA targets of hsa_circRNA_102958. We identified that hsa_circRNA_102958 possesses a potential binding site for miR-585. Through luciferase reporter assay and RNA pulldown assay, we demonstrated their direct interaction. We also observed that miR-585 expression was inhibited by hsa_circRNA_102958. miR-585 is a poorly researched miRNA. Two previous studies indicate that miR-585 is an anti-tumor gene in lung cancer and gastric cancer.[@CIT0015],[@CIT0016] Whether miR-585 is involved in CRC remains unknown. In our study, we found that miR-585 expression was significantly downregulated in CRC tissues. Our data also suggested that miR-585 is a tumor suppressor in CRC. Afterwards, we further investigated the target genes of miR-585. By bioinformatics analysis, we identified CDC25B as a potential target. Through luciferase reporter assay, we demonstrated that CDC25B was directly targeted by miR-585. Additionally, we showed that miR-585 mimics directly suppressed CDC25B expression in CRC. CDC25B is a cell-cycle regulator. Many literatures have demonstrated its oncogenic function. For example, CDC25B suppression by miR-152 leads to cell-cycle arrest of endometrial cancer cells.[@CIT0017] Cdc25B upregulation promotes cell cycle progression and contributes to melanoma.[@CIT0018] The role of CDC25B in CRC still remains unclear. In our study, we also demonstrated that CDC25B expression was upregulated by hsa_circRNA_102958 through inhibiting miR-585. Moreover, we showed that CDC25B expression was increased in CRC tissues. Additionally, restoration of CDC25B significantly rescued the proliferation, migration and invasion of hsa_circRNA_102958-silenced CRC cells. Thus, our findings demonstrated the oncogenic roles of CDC25B in CRC.

Notably, in the future study, whether circRNAs could be used for diagnosis or served as therapeutic targets should be researched in the future work. And our work also has some limitations. For example, we did not study the correlation between circRNA expression and clinical features.

In summary, we confirmed the high expression of hsa_circRNA_102958 in CRC tissues. We also demonstrated the oncogenic roles of hsa_circRNA_102958 by promoting proliferation, migration and invasion of CRC cells. Finally, we revealed a novel mechanism. We showed that hsa_circRNA_102958/miR-585/CDC25B axis participates in CRC progression.
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